Sunday, 26 September 2021


Dynex DSX ELISA gets China FDA nod

26 September 2013 | Regulatory | By BioSpectrum Bureau

The CFDA approval for the DSX system is effective for four years

The CFDA approval for the DSX system is effective for four years

Singapore: Dynex Technologies received approval from China's Food and Drug Administration (CFDA) to market the DSX automated enzyme-linked immunosorbent assay (ELISA) processing system in China.

The DSX is Dynex's industry leading automated ELISA processing system for diagnostic assays in clinical laboratories, capable of quickly and accurately handling four microplates per assay run, greatly reducing required manual technician time while improving the speed and reliability of test results.

The CFDA approval for the DSX system is effective for four years and allows Dynex to provide broader automation options to assay developers and clinical technologists throughout China.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account